Literature DB >> 16384825

Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.

Francesco Locatelli1, Simeone Andrulli, Bruno Memoli, Camilla Maffei, Lucia Del Vecchio, Stefano Aterini, Walter De Simone, Antonella Mandalari, Giuliano Brunori, Marcello Amato, Bruno Cianciaruso, Carmine Zoccali.   

Abstract

BACKGROUND: Chronic kidney disease patients who are resistant to erythropoietin (EPO) treatment may suffer from malnutrition and/or inflammation.
METHODS: In a cross-sectional study of haemodialysis patients, we investigated the relationship between the natural logarithm of the weekly EPO dose normalized for post-dialysis body weight and outcome measures of nutrition and/or inflammation [BMI, albumin and C reactive protein (CRP)] by means of multiple linear regression analysis. On the basis of the decile distribution of weekly EPO doses, we also evaluated four groups of patients: untreated, hyper-responders, normo-responders and hypo-responders.
RESULTS: Six hundred and seventy-seven adult haemodialysis patients were recruited from five Italian centres. BMI and albumin were lower in the hypo-responders than in the other groups (21.3+/-3.8 vs 24.4+/-4.7 kg/m(2), P<0.001; and 3.8+/-0.6 vs 4.1+/-0.4 g/dl, P<0.001), whereas the median CRP level was higher (1.9 vs 0.8 mg/dl, P = 0.004). The median weekly EPO dose ranged from 30 IU/kg/week in the hyper-responsive group to 263 IU/kg/week in the hypo-responsive group. Transferrin saturation linearly decreased from the hyper- to hypo-responsive group (37+/-15 to 25+/-10%, P = 0.003), without any differences in transferrin levels. Ferritin levels were lower in the hypo-responsive than in the other patients (median 318 vs 445 ng/ml, P = 0.01). At multiple linear regression analysis, haemoglobin, BMI, albumin, CRP and serum iron levels were independently associated with the natural logarithm of the weekly EPO dose (R(2) = 0.22).
CONCLUSIONS: Our findings support a clear association between EPO responsiveness and nutritional and inflammation variables in haemodialysis patients; iron deficiency is still a major cause of hypo-responsiveness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384825     DOI: 10.1093/ndt/gfk011

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  52 in total

1.  Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.

Authors:  Ana de Lurdes Agostinho Cabrita; Ana Pinho; Anabela Malho; Elsa Morgado; Marília Faísca; Hermínio Carrasqueira; Ana Paula Silva; Pedro Leão Neves
Journal:  Int Urol Nephrol       Date:  2010-07-17       Impact factor: 2.370

Review 2.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

3.  Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia.

Authors:  Takashi Maruyama; Terumi Higuchi; Toshio Yamazaki; Erina Okawa; Hideyuki Ando; Osamu Oikawa; Atsushi Inoshita; Kazuyoshi Okada; Masanori Abe
Journal:  Cardiorenal Med       Date:  2017-04-20       Impact factor: 2.041

Review 4.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

5.  Quality of life and protein-energy wasting in kidney transplant recipients.

Authors:  Akos Ujszaszi; Maria E Czira; Katalin Fornadi; Marta Novak; Istvan Mucsi; Miklos Z Molnar
Journal:  Int Urol Nephrol       Date:  2012-01-14       Impact factor: 2.370

6.  Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?

Authors:  Luca De Nicola; Francesco Locatelli; Giuseppe Conte; Roberto Minutolo
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

7.  Accumulation of retained nonfunctional arteriovenous grafts correlates with severity of inflammation in asymptomatic ESRD patients.

Authors:  Haimanot Wasse; Francesca Cardarelli; Christine De Staercke; W Craig Hooper; Qi Long
Journal:  Nephrol Dial Transplant       Date:  2012-10-22       Impact factor: 5.992

8.  Revisiting the association between altitude and mortality in dialysis patients.

Authors:  Bryan B Shapiro; Elani Streja; Connie M Rhee; Miklos Z Molnar; Leeka Kheifets; Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Hemodial Int       Date:  2014-01-15       Impact factor: 1.812

9.  Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study.

Authors:  Rieko Eriguchi; Masatomo Taniguchi; Toshiharu Ninomiya; Hideki Hirakata; Satoru Fujimi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  J Nephrol       Date:  2014-07-31       Impact factor: 3.902

10.  Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness.

Authors:  Angel L M de Francisco; Peter Stenvinkel; Sophie Vaulont
Journal:  NDT Plus       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.